Effective Preparation of [18F]Flumazenil Using Copper-Mediated Late-Stage Radiofluorination of a Stannyl Precursor
Details
Publication Year 2022-09-13,Volume 27,Issue #18,Page 5931
Journal Title
Molecules
Publication Type
Research article
Abstract
(1) Background: [18F]Flumazenil 1 ([18F]FMZ) is an established positron emission tomography (PET) radiotracer for the imaging of the gamma-aminobutyric acid (GABA) receptor subtype, GABAA in the brain. The production of [18F]FMZ 1 for its clinical use has proven to be challenging, requiring harsh radiochemical conditions, while affording low radiochemical yields. Fully characterized, new methods for the improved production of [18F]FMZ 1 are needed. (2) Methods: We investigate the use of late-stage copper-mediated radiofluorination of aryl stannanes to improve the production of [18F]FMZ 1 that is suitable for clinical use. Mass spectrometry was used to identify the chemical by-products that were produced under the reaction conditions. (3) Results: The radiosynthesis of [18F]FMZ 1 was fully automated using the iPhase FlexLab radiochemistry module, affording a 22.2 +/- 2.7% (n = 5) decay-corrected yield after 80 min. [18F]FMZ 1 was obtained with a high radiochemical purity (>98%) and molar activity (247.9 +/- 25.9 GBq/micromol). (4) Conclusions: The copper-mediated radiofluorination of the stannyl precursor is an effective strategy for the production of clinically suitable [18F]FMZ 1.
Keywords
*Copper/chemistry; *Flumazenil; Fluorine Radioisotopes/chemistry; Positron-Emission Tomography/methods; Radiopharmaceuticals; gamma-Aminobutyric Acid; Flumazenil 1; Gabaa; PET imaging; benzodiazepine; radiochemistry; radiofluorination; stannane; stannyl
Department(s)
Cancer Imaging
PubMed ID
36144667
Open Access at Publisher's Site
https://doi.org/10.3390/molecules27185931
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-11-01 04:30:28
Last Modified: 2024-11-01 04:31:35

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙